GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

Kexing Biopharm Co 688136.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

15.30

-1.48%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Kexing Biopharm Co

Its shares trade on Shanghai under the ticker 688136.SS. It has been listed since 14 December 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.54bn and net income of CN¥159.4m. At that date it held total assets of CN¥3.53bn and shareholders' equity of CN¥1.75bn.

Kexing Biopharm Co., Ltd. engages in the research and development, production, and sale of recombinant protein therapeutics and microbiota agents. The company is headquartered in Jinan, Shandong. The company went IPO on 2020-12-14. The firm's main products include Sinogen human interferon α1b for injection, Eposino human erythropoietin injection (CHO cell), human granulocyte colony-stimulating factor injection, Kehuang capsules Chinese patent medicine, Arketin bevacizumab injection, Ahrasin adalimumab solution for injection and others. The firm focuses on the treatment of antiviral, tumor and immunity, blood, digestion, degenerative diseases and other therapeutic areas. The firm mainly operates its businesses in the domestic and overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
14 Dec 2020
Employees
947
Website
kexing.com ↗

Leadership

Pay as last reported

  • Mr. Xueqin DengChairman of the Board, since 2019
  • Ms. Xiaoqin WangChief Financial Officer, Secretary of the Board, Director, since 2019CN¥738,600
  • Mr. Yanqing ZhaoGeneral Manager, Director, since 2019CN¥1.1m
  • Ms. Ning CuiDeputy General Manager, Director, since 2019CN¥694,400
  • Mr. Hongjie MaDeputy General ManagerCN¥831,700
  • Mr. Suofu QinDeputy General ManagerCN¥1.3m
  • Mr. Ke ShaoDeputy General ManagerCN¥1.4m
  • Mr. Hongzhong CaoIndependent DirectorCN¥180,000
  • Mr. An TangIndependent DirectorCN¥180,000
  • Ms. Jianhong TaoIndependent DirectorCN¥180,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Jinan, Shandong with 947 employees
  • Offers a diverse product portfolio including recombinant protein therapeutics and microbiota agents
  • Operates in both domestic and overseas markets

Weaknesses

  • No specific weaknesses mentioned in the provided information
  • No details on financial performance or market share provided
  • No mention of competitive advantages or unique technologies

Opportunities

  • Growth potential in the biotechnology sector
  • Expansion into new therapeutic areas such as antiviral, tumor, and immunity treatments
  • Potential for increased market presence in overseas markets

Threats

  • Competition in the biotechnology industry
  • Regulatory challenges in drug development and approval
  • Dependence on specific product lines for revenue

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.